Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 150,072	$ 128,994
Marketable securities	241,402	213,591
Accounts receivable, net of reserves of $5,054 in 2016 and $5,128 in 2015	204,701	188,318
Inventories	168,468	188,833
Deferred income tax assets		39,829
Other current assets	63,457	62,069
Total current assets	828,100	821,634
Long-Term Assets:
Property and equipment, net	349,664	333,026
Goodwill	180,952	178,934
Intangible assets, net	47,566	55,909
Other long-term assets	94,088	85,490
Total long-term assets	672,270	653,359
TOTAL ASSETS	1,500,370	1,474,993
Current Liabilities:
Accounts payable	44,127	52,648
Accrued liabilities	202,074	205,530
Line of credit	488,000	573,000
Current portion of deferred revenue	26,007	25,583
Total current liabilities	760,208	856,761
Long-Term Liabilities:
Deferred income tax liabilities	20,571	49,389
Long-term debt	599,137	597,085
Long-term deferred revenue, net of current portion	30,874	27,055
Other long-term liabilities	34,594	28,698
Total long-term liabilities	685,176	702,227
Total liabilities	1,445,384	1,558,988
Commitments and Contingencies (Note 13)
Stockholders’ Equity (Deficit):
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 103,120 and 102,237 shares in 2016 and 2015, respectively	10,312	10,258
Additional paid-in capital	994,299	940,534
Deferred stock units: Outstanding: 231 and 240 units in 2016 and 2015, respectively	5,470	5,409
Retained earnings	488,033	318,356
Accumulated other comprehensive loss	(35,081)	(42,265)
Treasury stock, at cost: 13,413 and 12,242 shares in 2016 and 2015, respectively	(1,408,183)	(1,316,417)
Total IDEXX Laboratories, Inc. stockholders’ equity (deficit)	54,850	(84,125)
Noncontrolling interest	136	130
Total stockholders’ equity (deficit)	54,986	(83,995)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 1,500,370	$ 1,474,993